RecruitingRecruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186 · Plexium, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
About this study
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies.
The study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which participants will be assessed for eligibility, a Treatment Phase beginning on Cycle 1 Day 1 and consisting of consecutive 28-day cycles, an End of Treatment Visit, and a Post-Treatment Follow-Up Phase.
Participants will receive their assigned dose of PLX-61639 administered orally, once daily until progression/relapse, intolerance, death, or withdrawal from study treatment by the Investigator or participant.
Eligibility criteria
Key Inclusion Criteria:
* Participants with locally advanced or metastatic, relapsed/refractory, solid tumors harboring a SMARCA4 loss-of-function mutation that have progressed on, are intolerant of, or not otherwise candidates for available approved therapies
* Adequate liver bone marrow, coagulation, renal, and cardiopulmonary function
* Measurable disease per RECIST 1.1
* ECOG PS of 0 or 1
Key Exclusion Criteria:
* Germline SMARCA4 mutations
* Known SMARCA2 mutation or loss of expression
* Symptomatic CNS disease
* Prior treatment with another SMARCA2-directed therapy
* History of other malignancies
* Clinically significant heart disease
* Uncontrolled hypertension
* Prolongation of QT interval
Study design
Enrollment target: 155 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-12-01
Estimated completion: 2030-09
Last updated: 2026-06-12
Interventions
Drug: PLX-61639
Primary outcomes
- • Treatment Emergent Adverse Events (From enrollment to 28 days after the last dose of PLX-61639)
- • Dose-Limiting Toxicities (From enrollment to 28 days after first dose of PLX-61639)
Sponsor
Plexium, Inc. · industry
Contacts & investigators
ContactClinical Operations · contact · ClinicalTrials@Plexium.com · 619-631-3091
InvestigatorChief Medical Officer · study_director, Plexium, Inc.
All locations (10)
Research SiteRecruiting
Scottsdale, Arizona, United States
Research SiteRecruiting
Duarte, California, United States
Research SiteRecruiting
Orange, California, United States
Research SiteRecruiting
Boston, Massachusetts, United States
Research SiteRecruiting
St Louis, Missouri, United States
Research SiteRecruiting
New York, New York, United States
Research SiteRecruiting
Durham, North Carolina, United States
Research SiteRecruiting
Cleveland, Ohio, United States
Research SiteRecruiting
San Antonio, Texas, United States
Research SiteRecruiting
Fairfax, Virginia, United States